Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
27 June 2024 - 1:45AM
Saint-Herblain (France), June 26, 2024 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced that all the resolutions recommended by
the Board of Directors were approved by the shareholders at its
Combined General Meeting (CGM) held today in Lyon, France.
Among the adopted resolutions were approval of
the 2023 financial statements, delegations for the management board
to increase Valneva’s share capital and/or issue financial
instruments, and the appointment of a new director to its
Board.
Ms. Danièle Guyot-Caparros was appointed to
Valneva’s Board of Directors for a three-year term. Ms.
Guyot-Caparros has a proven track record in finance and business
operations. She started her career in Audit and Corporate Finance
with PWC specializing in the Chemical/Pharma Industry. In 1992, she
joined Rhône-Poulenc-Rorer (later Aventis and Sanofi) where she
held several senior finance positions (CFO Global R&D, CFO
Europe, Group Planning). She also held responsibilities in business
development, pricing, and portfolio management. In 2008, she became
Senior Advisor for Deloitte France to support the development of
the Life Sciences and Health Care Industry practice. Ms.
Guyot-Caparros is also an experienced non-executive director with a
focus on Biotech/Medtech. She sat on Diaxonhit’s (now Eurobio
Scientific) and ONXEO’s Board of Directors and chaired Supersonic
Imagine’s and ONXEO’s audit committees. In October 2022, she joined
the board of DBV Technologies, listed on Euronext Paris and Nasdaq,
and is member of the audit committee as well as of the compensation
committee. She is a graduate from ICN (Institut Commercial de
Nancy), with a major in finance and accounting. She holds a
chartered accountant degree and a certificate of corporate
governance/non-executive director from IFA-Science-Po.
The AGM’s voting results will be made available
in the “Investors & Media” section of Valneva’s corporate
website in the coming days.
About Valneva SEWe are a
specialty vaccine company that develops, manufactures, and
commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing either first-, best- or
only-in-class vaccine solutions.We have a strong track record,
having advanced multiple vaccines from early R&D to approvals,
and currently market three proprietary travel vaccines, including
the world’s first and only chikungunya vaccine, as well as certain
third-party vaccines.Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, as well as
vaccine candidates against the Zika virus and other global public
health threats. More information is available at
www.valneva.com.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates, to regulatory approval of product candidates and review
of existing products. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2024_06_26_VLA_Post_CGM_PR_EN_Final
Valneva (EU:VLA)
Historical Stock Chart
From Aug 2024 to Oct 2024
Valneva (EU:VLA)
Historical Stock Chart
From Oct 2023 to Oct 2024